175 related articles for article (PubMed ID: 25180175)
1. Phosphoproteomic analysis of gossypol-induced apoptosis in ovarian cancer cell line, HOC1a.
Jin L; Chen Y; Mu X; Lian Q; Deng H; Ge R
Biomed Res Int; 2014; 2014():123482. PubMed ID: 25180175
[TBL] [Abstract][Full Text] [Related]
2. Gossypol induces apoptosis in ovarian cancer cells through oxidative stress.
Wang J; Jin L; Li X; Deng H; Chen Y; Lian Q; Ge R; Deng H
Mol Biosyst; 2013 Jun; 9(6):1489-97. PubMed ID: 23532321
[TBL] [Abstract][Full Text] [Related]
3. Proapoptotic protein Smac mediates apoptosis in cisplatin-resistant ovarian cancer cells when treated with the anti-tumor agent AT101.
Hu W; Wang F; Tang J; Liu X; Yuan Z; Nie C; Wei Y
J Biol Chem; 2012 Jan; 287(1):68-80. PubMed ID: 22052903
[TBL] [Abstract][Full Text] [Related]
4. Combined gossypol and zoledronic acid treatment results in synergistic induction of cell death and regulates angiogenic molecules in ovarian cancer cells.
Atmaca H; Gorumlu G; Karaca B; Degirmenci M; Tunali D; Cirak Y; Purcu DU; Uzunoglu S; Karabulut B; Sanli UA; Uslu R
Eur Cytokine Netw; 2009 Sep; 20(3):121-30. PubMed ID: 19825521
[TBL] [Abstract][Full Text] [Related]
5. -(-)Gossypol promotes the apoptosis of bladder cancer cells in vitro.
Macoska JA; Adsule S; Tantivejkul K; Wang S; Pienta KJ; Lee CT
Pharmacol Res; 2008; 58(5-6):323-31. PubMed ID: 18840529
[TBL] [Abstract][Full Text] [Related]
6. Gossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAIL.
Sung B; Ravindran J; Prasad S; Pandey MK; Aggarwal BB
J Biol Chem; 2010 Nov; 285(46):35418-27. PubMed ID: 20837473
[TBL] [Abstract][Full Text] [Related]
7. Hyper-phosphorylation of Sequestosome-1 Distinguishes Resistance to Cisplatin in Patient Derived High Grade Serous Ovarian Cancer Cells.
Nguyen EV; Huhtinen K; Goo YA; Kaipio K; Andersson N; Rantanen V; Hynninen J; Lahesmaa R; Carpen O; Goodlett DR
Mol Cell Proteomics; 2017 Jul; 16(7):1377-1392. PubMed ID: 28455291
[TBL] [Abstract][Full Text] [Related]
8. Proteomic analysis of gossypol induces necrosis in multiple myeloma cells.
Xu R; Tian E; Tang H; Liu C; Wang Q
Biomed Res Int; 2014; 2014():839232. PubMed ID: 25197664
[TBL] [Abstract][Full Text] [Related]
9. The PPARγ agonist rosiglitazone sensitizes the BH3 mimetic (-)-gossypol to induce apoptosis in cancer cells with high level of Bcl-2.
Li X; He J; Li B; Gao M; Zeng Y; Lian J; Shi C; Huang Y; He F
Mol Carcinog; 2018 Sep; 57(9):1213-1222. PubMed ID: 29856104
[TBL] [Abstract][Full Text] [Related]
10. Involvement of Smac, p53, and caspase pathways in induction of apoptosis by gossypol in human retinoblastoma cells.
Hsiao WT; Tsai MD; Jow GM; Tien LT; Lee YJ
Mol Vis; 2012; 18():2033-42. PubMed ID: 22876131
[TBL] [Abstract][Full Text] [Related]
11. Combination of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells.
Karaca B; Atmaca H; Bozkurt E; Kisim A; Uzunoglu S; Karabulut B; Sezgin C; Sanli UA; Uslu R
Mol Biol Rep; 2013 Jun; 40(6):3925-33. PubMed ID: 23269627
[TBL] [Abstract][Full Text] [Related]
12. ApoG2 as the most potent gossypol derivatives inhibits cell growth and induces apoptosis on gastric cancer cells.
Xin J; Zhan YH; Xia LM; Zhu HW; Nie YZ; Liang JM; Tian J
Biomed Pharmacother; 2013 Feb; 67(1):88-95. PubMed ID: 23201009
[TBL] [Abstract][Full Text] [Related]
13. The effect of racemic gossypol and at-101 on angiogenic profile of ovcar-3 cells: a preliminary molecular framework for gossypol enantiomers.
Varol U; Karaca B; Tunali D; Degirmenci M; Cirak Y; Purcu DU; Uzunoglu S; Sezgin C; Karabulut B; Sanli UA; Uslu R
Exp Oncol; 2009 Dec; 31(4):220-5. PubMed ID: 20010531
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of Fas/Fas ligand-mediated apoptosis by gossypol in an immortalized human alveolar lung cancer cell line.
Chang JS; Hsu YL; Kuo PL; Chiang LC; Lin CC
Clin Exp Pharmacol Physiol; 2004 Oct; 31(10):716-22. PubMed ID: 15554914
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness.
Muñoz-Galván S; Felipe-Abrio B; Verdugo-Sivianes EM; Perez M; Jiménez-García MP; Suarez-Martinez E; Estevez-Garcia P; Carnero A
Mol Cancer; 2020 Jan; 19(1):7. PubMed ID: 31926547
[TBL] [Abstract][Full Text] [Related]
16. Gossypol reduction of tumor growth through ROS-dependent mitochondria pathway in human colorectal carcinoma cells.
Ko CH; Shen SC; Yang LY; Lin CW; Chen YC
Int J Cancer; 2007 Oct; 121(8):1670-9. PubMed ID: 17597109
[TBL] [Abstract][Full Text] [Related]
17. Akt activation by Ca
Gocher AM; Azabdaftari G; Euscher LM; Dai S; Karacosta LG; Franke TF; Edelman AM
J Biol Chem; 2017 Aug; 292(34):14188-14204. PubMed ID: 28634229
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of (-)-gossypol-induced apoptosis in human prostate cancer cells.
Huang YW; Wang LS; Chang HL; Ye W; Dowd MK; Wan PJ; Lin YC
Anticancer Res; 2006; 26(3A):1925-33. PubMed ID: 16827126
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib sensitizes (-)-gossypol-induced growth suppression in androgen-independent prostate cancer cells via Mcl-1 inhibition and Bak activation.
Lian J; Ni Z; Dai X; Su C; Smith AR; Xu L; He F
Mol Cancer Ther; 2012 Feb; 11(2):416-26. PubMed ID: 22188816
[TBL] [Abstract][Full Text] [Related]
20. Synergistic cytotoxicity of Bcl-xL inhibitor, gossypol and chemotherapeutic agents in non-Hodgkin's lymphoma cells.
Li ZM; Jiang WQ; Zhu ZY; Zhu XF; Zhou JM; Liu ZC; Yang DJ; Guang ZZ
Cancer Biol Ther; 2008 Jan; 7(1):51-60. PubMed ID: 17938578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
